Get notified when ENGN files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Passive Foreign Investment Company (new) — PFIC status can trigger adverse U.S. tax consequences for U.S. investors, including potential current taxation on unrealized gains.
NASDAQ: ENGN enGene Therapeutics Inc. 424B5

enGene files up to $100M at-the-market offering of common shares via Leerink Partners

Filed March 9, 2026 · ~1 min read

Key Changes

  • high

    enGene may sell up to $100 million of common shares from time to time through Leerink Partners as sales agent.

    The Offering verify on EDGAR →
  • medium

    Proceeds go to the company for general corporate purposes, including development and potential commercialization of detalimogene.

    Use of Proceeds verify on EDGAR →
  • high

    New investors would experience immediate dilution of $3.89 per share based on 66,989,466 shares outstanding as of January 31, 2026.

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FPS 10-K) is open in full — no account needed.

Partner

Trade ENGN commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify